Eledon Secures Natera Partnership for Planned Phase 3 Kidney Transplant Trial
ELDN has more than doubled off its 52-week low of $1.35.
Summary
Eledon Pharmaceuticals announced a strategic partnership with Natera, which will provide Prospera™ monitoring for Eledon's planned Phase 3 kidney transplant trial. This collaboration is a significant step for Eledon as it prepares to initiate the pivotal Phase 3 trial for its lead drug candidate in late 2026. The move follows recent positive long-term Phase 2 results and addresses the company's need to advance its clinical pipeline, as indicated by recent financing activities and widened net losses.
At the time of this announcement, ELDN was trading at $4.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $305.7M. The 52-week trading range was $1.35 to $4.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.